<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05046821</url>
  </required_header>
  <id_info>
    <org_study_id>HS# 2021-6779</org_study_id>
    <secondary_id>R01AR078340-01</secondary_id>
    <nct_id>NCT05046821</nct_id>
  </id_info>
  <brief_title>Sporadic Inclusion Body Myositis Natural History Study</brief_title>
  <acronym>INSPIRE-IBM</acronym>
  <official_title>Influence of NT5c1A Antibodies on Disease Progression, Clinical Phenotype and Blood and Muscle Biomarkers in Sporadic Inclusion Body Myositis - A Prospective Evaluation (INSPIRE-IBM Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective natural history study on patients with clinically defined sIBM.&#xD;
      Participants will be assessed every 6 months over two years (five visits total). We will&#xD;
      include 150 participants, enrolled across 13 sites, with sporadic IBM, diagnosed according to&#xD;
      established criteria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective natural history study on patients with clinically defined sIBM.&#xD;
      Participants will be assessed every 6 months over two years (five visits total). We will&#xD;
      include 150 participants with sporadic IBM, diagnosed according to established criteria.&#xD;
      Participants will require an routine serum sample via blood draw to evaluate for NT5c1A&#xD;
      antibody status. This testing will be performed at Washington University School of Medicine&#xD;
      in the Neuromuscular Laboratory. Investigators will be blinded to antibody status. A subset&#xD;
      of participants (40) will undergo a muscle biopsy at the Baseline visit.&#xD;
&#xD;
      Aim 1. To determine for the first time whether NT5c1A antibodies mediate disease progression&#xD;
      over a two-year interval in patients with sIBM.&#xD;
&#xD;
      We will perform a prospective, non-interventional, observational study on patients with sIBM&#xD;
      with follow up and evaluations every 6 months over a two-year time frame. Primary analyses&#xD;
      are: 1) the rates of disease progression and severity as measured by rates of decline in IBM&#xD;
      Functional Rating Scale (IBMFRS) score and Timed Get Up and Go (TUG); 2) the presence or&#xD;
      absence of serum antibodies to NT5c1A; and 3) the presence and frequency of variant T-cells&#xD;
      in the serum and skeletal muscle.&#xD;
&#xD;
      Aim 2. To perform a detailed morphological, histochemical and immunohistochemical analysis of&#xD;
      fresh muscle biopsy specimens obtained from a subset of patients with sIBM.&#xD;
&#xD;
      Aim 3. To characterize the distribution of &quot;immunosenescent&quot; lymphocytes in circulating blood&#xD;
      from patients with sIBM.&#xD;
&#xD;
      Aim 4. To quantify the decline in the respiratory function of sIBM patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>IBMFRS</measure>
    <time_frame>2 years</time_frame>
    <description>Inclusion Body Myositis Functional Rating Scale (Questionnaire)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Timed Up and Go (TUG)</measure>
    <time_frame>2 years</time_frame>
    <description>Stand up from a chair, walk 3 meters, sit back down in chair</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of immunophenotypic abnormalities in blood and muscle</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Forced Vital Capacity (FVC) (sitting)</measure>
    <time_frame>2 years</time_frame>
    <description>breathing test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Manual Muscle Testing</measure>
    <time_frame>2 years</time_frame>
    <description>muscle strength testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand Held Dynamometry</measure>
    <time_frame>2 years</time_frame>
    <description>muscle strength testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sydney Swallow Questionnaire</measure>
    <time_frame>2 years</time_frame>
    <description>swallow ability questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EAT-10 Questionnaire</measure>
    <time_frame>2 years</time_frame>
    <description>swallow ability questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH PROMIS questionnaires</measure>
    <time_frame>2 years</time_frame>
    <description>quality of life questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IBM-HI</measure>
    <time_frame>2 years</time_frame>
    <description>functional ability questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (supine)</measure>
    <time_frame>2 years</time_frame>
    <description>breathing test done while lying down</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Inspiratory Pressure/Maximum Expiratory Pressure</measure>
    <time_frame>2 years</time_frame>
    <description>breathing tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sporadic inclusion body myositis physical functioning assessment (sIFA)</measure>
    <time_frame>2 years</time_frame>
    <description>functional ability questionnaire</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Sporadic Inclusion Body Myositis</condition>
  <condition>Inclusion Body Myositis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA and RNA will be isolated from blood and muscle samples and stored for future research&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Paticipants age 40 and older with sporadic IBM, diagnosed according to established&#xD;
        criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ages 40 years and older&#xD;
&#xD;
          2. Fulfills ENMC 2011 criteria of clinically definite or probable sporadic Inclusion body&#xD;
             myositis (sIBM)&#xD;
&#xD;
          3. Disease onset is within the past 10 years of the time of Baseline visit&#xD;
&#xD;
          4. Able to participate and comply with study related procedures&#xD;
&#xD;
          5. Able to provide written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current or very recent use (within last 6 months of the Baseline visit) of&#xD;
             immunomodulation or immunosuppression therapy.&#xD;
&#xD;
          2. Current or very recent use (within last 90 days of the Baseline visit) of an&#xD;
             investigational medication or therapy.&#xD;
&#xD;
          3. Co-existing significant medical or surgical conditions that, in the opinion of the&#xD;
             investigator, will influence study participation or alter natural history.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tahseen Mozaffar, MD FAAN, FANA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Wencel, BS</last_name>
    <phone>(714) 456-2525</phone>
    <email>mwencel@hs.uci.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Avelar</last_name>
    <phone>(714) 506-2665</phone>
    <email>jbavelar@hs.uci.edu</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myositis</mesh_term>
    <mesh_term>Myositis, Inclusion Body</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

